Navigation Links
Reportlinker Adds Triple Analysis: Colorectal Cancer, Leukemia and Apoptosis
Date:5/3/2011

NEW YORK, May 3, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Triple Analysis: Colorectal Cancer, Leukemia and Apoptosis

http://www.reportlinker.com/p0284934/Triple-Analysis-Colorectal-Cancer-Leukemia-and-Apoptosis.html

This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Leukemia and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Colorectal Cancer

The colorectal cancer report part comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 investigators, from Ceased to Marketed. This part extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer.

This part is based on the following publication:

A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market

Part II: Leukemia

The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and eight subindications of leukemia.

This part is based on the following publication:

A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part III: Apoptosis

The apoptosis report part comprises defined and up to date development strategies for 171 apoptotic drugs in oncology (519 projects) within the portfolio of 125 investigators, from Ceased to Pre-registration. This report part extensively analyses 146 identified targets of apoptotic drugs, organized into 120 drug target strategies, and assesses them in 53 different cancer indications.

This part is based on the following publication:

Apoptotic Therapeutics in Oncology - Where to Commercialize?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Colorectal Cancer

5.1 The Scope of this Report 28

6 Consider the Therapeutic Target Among Colorectal Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (210 Drug Targets) 32-451

7 Emerging New Products to Established Ones: Drug Target Strategies of Colorectal Cancer Drugs by their Highest Stage of Development (205 Drug Target Strategies and 347 Colorectal Cancer Drugs) 452-699

8 Compound Strategies at Work: Competitive Benchmarking of Colorectal Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-745

9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Colorectal Cancer Drug Pipeline by Investigator (182 Companies) 746-1,039

10 Disclaimer 1040

11 Drug Index 1041

12 Company Index 1050

Figures: Includes 6 Figures

Tables: Includes 242 Tables

Total Number of Pages: 1,056

Part II: Leukemia

5.1 The Scope of this Report 29

6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443

7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727

8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728

9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762

10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129

11 Disclaimer 1130

12 Drug Index 1131

13 Company Index 1140

Figures: Includes 6 Figures

Tables: Includes 253 Tables

Total Number of Pages: 1,147

Part III: Apoptosis

5.1 The Scope of this Report 27

6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (146 Drug Targets) 32-276

7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Apoptotic Therapeutic Pipeline? (120 Drug Target Strategies and 171 Drugs) 277-311

8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Drugs in Oncology by Compound Type (7 Different Compound Strategies) 312-355

9 Selecting Cancer Indications for Apoptotic Therapeutics (53 Cancer Indications) 356-440

10 Portfolio Planning: Competitive Benchmarking of Apoptotic Cancer Therapeutic Pipeline by Investigator (125 Investigators) 441-793

12 Drug Index 794

13 Company Index 799

Figures: Includes 6 Figures

Tables: Includes 248 Tables

Total Number of Pages: 803

To order this report:

: Triple Analysis: Colorectal Cancer, Leukemia and Apoptosis

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Probiotics and Prebiotics in Clinical Nutrition
2. Reportlinker Adds Triple Analysis: Leukemia, Pancreatic Cancer and Prostate Cancer
3. Reportlinker Adds Cancer Reports Bundle
4. Reportlinker Adds Medical Imaging Technologies for Oncology Diagnostics: The Global Market
5. Reportlinker Adds Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies
6. Reportlinker Adds Advanced Lung Cancer in Patient Smoker with Squamous Cell: Clinical Insights from a US Oncologists Survey
7. Reportlinker Adds Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma
8. Reportlinker Adds Pharmaceutical Key Trends 2011 - Prescription Pharmaceutical Sales Overview
9. Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify
10. Reportlinker Adds Pharmaceutical Key Trends 2011 - Biosimilar Market Overview
11. Reportlinker Adds Pharmaceutical Key Trends 2011 - Brand Erosion Post-Patent Expiry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , May 24, 2016 ... médica para ayudar a los médicos a compartir sus ... pacientes a escala mundial. Profesionales médicos de Europa, África, ... se han apuntado a la aplicación, que combina la ... un entorno totalmente seguro. Educación   ...
(Date:5/24/2016)...   , Study met ... and superiority in , Excellent plus ... of the ascending colon   , ... B.V. today announced new positive data from the phase III MORA ... standard 2 litre PEG with ascorbate. The study met both primary ...
(Date:5/24/2016)... , May 24, 2016 ARANZ ... for the healthcare sector, has been named the Coretex Hi-Tech ... Awards 2016. Dr Bruce Davey , CEO ... our team.  It,s really good to be recognised for the ... Our products are used in 35 countries around the world ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... Today Omega Institute, a ... 11 innovative workshops and training opportunities in the growing field of ... of individuals who are dealing with specific health issues—including injuries, illnesses, and temporary or ...
(Date:5/25/2016)... ... 2016 , ... Cheryl Bowker of Bowker Insurance Group has been presented with ... Legacy Award. McKenna ran one of Allstate’s most successful agencies for 48 years, but ... knew him. The award named for him is not given every year, but only ...
(Date:5/25/2016)... FL (PRWEB) , ... May 25, 2016 , ... The ... dive into the unique integrative medical wellness offerings of Europe, a continent that pioneered ... Tyrol, Austria will hear from numerous pioneers in medical wellness, including Henri Chenot, Founder ...
(Date:5/25/2016)... FL (PRWEB) , ... May 25, 2016 , ... ... Cross Benefit Clearinghouse supporting the real time adjudication of medical service claims by ... providers using their current medical claims management software. The TransactRx Cross Benefit Clearinghouse ...
(Date:5/25/2016)... ... May 25, 2016 , ... Conrad Siegel Actuaries, delivering ... and Prescription Drug survey , an employee benefits survey measuring how ... in December 2015, indicates that employers are turning to consumer directed health care ...
Breaking Medicine News(10 mins):